ABT-199, An Ultimate Comfort!

For immunohistochemistry, sections (4??m) were incubated with the primary antibody (anti-p-mTOR, diluted 1?:?1000), followed by a peroxidase-conjugated secondary antibody. Negative control tumour sections were treated identically to other sections except that the primary antibody was not included in the http://www.selleckchem.com/products/abt-199.html staining. Breast, skin and kidney tissue from archival specimens were used as positive controls for p-mTOR expression. Staining was quantified using a DAKO ACIS III image analyser as an intensity score (scale 0�C255). Differences in staining were assessed between pathological subgroups using the Wilcoxon rank-sum and Kruskal�CWallis tests as appropriate. We assessed mTOR expression in a panel of five human bladder cancer cell lines by immunoblotting whole cell lysates from cultured cells. As shown in Fig.?1, mTOR, as well as p-mTOR, the activated form of the protein, were detected in 4/5 cell lines. Since mTOR has been shown to be a substrate of the PI3K/AKT signalling pathway [25], we evaluated AKT activity in these UC cells, and found highly active AKT in all lines tested, although 253J cells, a line derived from an invasive tumour, did not demonstrate detectable levels of http://www.selleckchem.com/products/ABT-263.html p-AKT. We also noted high activity of ERK, another upstream regulator of mTOR, and p-ERK, in all cell lines tested. We next examined the effect of rapamycin, a known mTOR inhibitor [8], on UC cell viability. Because one of the objectives of our study was to assess whether mTOR inhibition might be a useful addition to the current chemotherapeutic regimens for advanced bladder cancer, we chose two lines, 253J and UMUC3, that showed high levels of mTOR expression (Fig.?1) and that were derived from invasive tumours, for the remainder of the investigations. We found that rapamycin significantly reduced the number of viable cells in both 253J (P= 0.004) and UMUC3 (P http://www.selleck.cn/products/CP-690550.html for both; Fig.?2B). Given the effects observed after treatment with rapamycin on the number of viable UC cells, we sought to determine whether these findings were attributable to changes in cell proliferation or apoptosis. Specifically, we evaluated the impact of treatment on UC cell-cycle progression using flow cytometry. We found that, for both cell lines, 48?h of treatment with 5?nM rapamycin resulted in a modest but significant increase in the proportion of cells in the G0/G1 phase, and a corresponding decrease in the number of cells in the S phase (Table?1).